These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 33941080)

  • 21. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study.
    Okonkwo R; Tockhorn-Heidenreich A; Stroud C; Paget MA; Matharu MS; Tassorelli C
    J Headache Pain; 2021 Sep; 22(1):113. PubMed ID: 34592919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
    Zhou J; Zhong L; Chowdhury D; Skorobogatykh K; Luo G; Yang X; Zhang M; Sun L; Liu H; Qian C; Yu S
    J Headache Pain; 2023 Aug; 24(1):103. PubMed ID: 37542222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
    Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
    Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
    Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
    J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
    Barbanti P; Egeo G; Aurilia C; Altamura C; d'Onofrio F; Finocchi C; Albanese M; Aguggia M; Rao R; Zucco M; Frediani F; Filippi M; Messina R; Cevoli S; Carnevale A; Fiorentini G; Messina S; Bono F; Torelli P; Proietti S; Bonassi S; Vernieri F;
    J Headache Pain; 2022 Nov; 23(1):138. PubMed ID: 36316648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.
    Guerzoni S; Baraldi C; Castro FL; Cainazzo MM; Pani L
    Brain Behav; 2023 Jun; 13(6):e2799. PubMed ID: 37208838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
    Barbanti P; Orlando B; Egeo G; d'Onofrio F; Doretti A; Messina S; Autunno M; Messina R; Filippi M; Fiorentini G; Rotondi C; Bonassi S; Aurilia C
    Brain Sci; 2024 Jun; 14(7):. PubMed ID: 39061413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
    Ornello R; Casalena A; Frattale I; Caponnetto V; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Aug; 21(1):102. PubMed ID: 32799790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
    Tepper SJ; Dong Y; Vincent M; Wietecha LA
    Headache; 2023; 63(10):1380-1390. PubMed ID: 37132481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
    Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
    BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
    Citrome L; Sánchez Del Rio M; Dong Y; Nichols RM; Tockhorn-Heidenreich A; Foster SA; Stauffer VL
    Adv Ther; 2021 Aug; 38(8):4442-4460. PubMed ID: 34264500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.